Accounting for Microdosing Classic Psychedelics

Microdosing classic psychedelics (for example LSD and psilocybin) involves taking sub‑perceptual or very small doses with the aim of producing subtle improvements in mood, creativity, cognition, or functioning rather than the full psychedelic ‘‘trip’’. Popular and media attention to microdosing has emphasised potential benefits, but classic psychedelics remain illegal in many jurisdictions and social stigma persists. The paper uses the sociology of accounts — a framework distinguishing excuses (denials of responsibility) from justifications (acceptance of responsibility while arguing the act is permissible in context) — to examine how people who microdose linguistically manage potential stigma and align their behaviour with societal expectations. Beaton and colleagues set out to explore how people who currently or formerly microdosed classic psychedelics account for that behaviour when questioned. Using semistructured interviews, the study investigates whether participants offered excuses or justifications and identifies the specific justificatory themes they used to neutralise or normalise microdosing in social contexts.

The study used qualitative semistructured interviews with 30 participants who had experience microdosing classic psychedelics. Participants were recruited via criterion‑based sampling from Facebook groups and online discussion forums devoted to microdosing; an author posted study invitations and interested individuals contacted the research team. Eligible participants were at least 18 years old and had microdosed for at least 5 weeks within the prior year. The study adopted a common operational definition of microdosing (small doses taken on a regimented schedule for ≥5 weeks). Interviews occurred between June 2017 and January 2018 and were conducted by telephone or Facebook call, with participant consent for audio recording. Interview length ranged from about 30 to 75 minutes. The sample spanned multiple U.S. states (n = 12) and several other countries (n = 4); ages ranged 18–69 with a median of 31; 10 participants identified as women and 20 as men; racial/ethnic self‑identification included Asian (n = 1), Middle Eastern (n = 2), Hispanic/Latino (n = 3), and White (n = 24). Substance use patterns included psilocybin and LSD/1P‑LSD, with 6 participants using both, 13 using only psilocybin, and 11 using only LSD/1P‑LSD. Reported duration of microdosing ranged from 2 months to 5 years (mean ~1 year); 12 participants reported current or past larger‑dose psychedelic use and six reported never using psychedelics outside microdosing protocols. Interview topics covered initiation, motivations, perceived effects (positive or negative), procurement, dosing schedules, prior drug use, and concerns about detection. Transcripts were anonymised. Coding combined deductive codes drawn from the sociology of accounts literature with inductive, data‑driven codes to capture emergent justificatory themes.

Participants acknowledged legal penalties for possession of LSD and psilocybin but generally expected low risk of formal detection; their primary concern was reputational harm if friends, family, or employers discovered their microdosing. Many kept use secret from coworkers and family because of perceived negative public attitudes; illustrative quotes show fears of being labelled or judged and of workplace consequences such as drug testing. Contrary to offering excuses (denying responsibility), none of the 30 participants framed their microdosing as excused behaviour. Instead, all offered one or more justifications to reposition microdosing as acceptable. The investigators identified six recurring justificatory themes and report participant counts for each: denial of injury (n = 15), self‑sustaining (n = 23), self‑fulfillment (n = 30), appeal to loyalties (n = 16), appeal to normality (n = 19), and knowledgeableness (n = 12). Denial of injury: Half the sample (n = 15) stressed that microdosing caused no physical, mental, or emotional harm. Some compared microdosing favourably with over‑the‑counter medications or caffeine, while others emphasised no adverse impact on work, study, or mood. Representative participants denied experiencing negative effects and characterised microdosing as benign. Self‑sustaining: Twenty‑three participants framed microdosing as a coping or therapeutic strategy to relieve stress, anxiety, depression, or to aid recovery from heavier substance use. Several described microdosing as enabling them to manage overwhelming emotions or to reduce use of alcohol, tobacco, or illicit drugs; a few gave specific examples of quitting heroin or substantial reductions in other substance use coincident with microdosing. Self‑fulfillment: All 30 participants reported that microdosing enhanced personal wellbeing, cognition, creativity, or spirituality. Participants described improved mood, greater energy, increased focus, and enhanced capacity to process problems. This theme positioned microdosing as a tool for personal growth and prevention of problems rather than merely a remedial measure. Appeal to loyalties: Sixteen participants justified microdosing by emphasising benefits to close relationships. They reported that microdosing improved bonding with spouses, family, and friends, increased compassion and communication, or facilitated shared recreational experiences. Appeal to normality: Nineteen participants compared microdosing to socially accepted substances or medical treatments, framing it as analogous to prescription stimulants (e.g. Adderall), caffeine, alcohol, or as a legitimate therapeutic medicine (for anxiety or depression). Some cited clinical research or used cultural norms to argue microdosing should be treated as normal or medicinal. Knowledgeableness: Twelve participants reported curiosity and prior research as motives for trying microdosing; these participants emphasised experimentation and information gathering rather than an initial therapeutic intent. Overall, the data indicate participants accepted responsibility for microdosing and relied on culturally available vocabularies to neutralise potential stigma, using pragmatic, health‑oriented, relational, or normalising arguments.

Beaton and colleagues interpret the findings as showing that people who microdose classic psychedelics commonly reframe the practice as an instrumentally useful, socially acceptable activity rather than a deviant one. By deploying justificatory accounts — denial of injury, self‑sustaining, self‑fulfillment, appeal to loyalties, appeal to normality, and knowledgeableness — participants sought to align microdosing with conventional values such as self‑improvement, health maintenance, and responsible caretaking. The authors note that participants’ tone tended toward reasoned argument rather than apology; stigma was managed by keeping use private and by explaining microdosing in terms already legitimate in the culture (for example, comparison to supplements, coffee, or prescription medicines). The investigators acknowledge important limitations. The sample was purposive and interpretivist rather than probabilistic, so frequencies reported should not be generalised to the wider population of microdosers. Selection bias likely favoured people who viewed microdosing positively, and the interviewer’s social characteristics may have shaped responses. The authors emphasise that accounts are social constructions drawn from culturally available vocabularies; social location of speakers and audience contexts will influence justificatory repertoires, and microdosers from different backgrounds might employ different accounts. Finally, they caution that participant claims about benefits and lack of harm are subjective and not proof of clinical efficacy or safety. Directions for further work include examining how media coverage and decriminalisation efforts shape the legitimacy of microdosing accounts, and conducting more clinical research to evaluate the effectiveness and potential harms of microdosing under controlled conditions.